2024-07-11 16:21:37 ET
More on Nurix Therapeutics
- Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case
- Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
- Earnings week ahead: PepsiCo, Delta Air Lines, JPMorgan, Citigroup and more
- Nurix releases promising phase 1 data on NX-5948 for chronic lymphocytic leukemia
- Seeking Alpha’s Quant Rating on Nurix Therapeutics
Read the full article on Seeking Alpha
For further details see:
Nurix Therapeutics GAAP EPS of -$0.71 misses by $0.08, revenue of $12.09M misses by $9.69M